Horizon trial
Study / Research
A cardiovascular outcomes trial launched by Ionis/Novartis to study the effect of their antisense oligonucleotide on preventing major atherosclerotic cardiovascular events in patients with stable cardiovascular diseases.
Mentioned in 2 videos
Save the 2 videos on Horizon trial to your own pod.
Sign up free to keep building your knowledge base on Horizon trial as more episodes are added.
Videos Mentioning Horizon trial
210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.
Peter Attia MD
A cardiovascular outcomes trial launched by Ionis/Novartis to study the effect of their antisense oligonucleotide on preventing major atherosclerotic cardiovascular events in patients with stable cardiovascular diseases.
407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more
Peter Attia MD
A phase 3 trial for an anti-sense oligonucleotide that lowers Lp(a), expected to be released this year, but faced challenges due to a lower-than-expected event rate.